Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers

Ryanair reports a narrower net loss, while Regeneron's melanoma trial fails. The news impacts stock market movers. Ryanair's financial performance is improving.